Last week, the Northwest Biotherapeutics (OTCMKTS:NWBO) stock had been in the middle of a strong rally, but the situation has changed this week and the stock is down by 20% this morning at the time of writing.
The rally in the stock commenced when the company provided an update in relation to its manufacturing facility in Sawston, United Kingdom. Northwest revealed that it had submitted the application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for certifying its new facility.
It is a major milestone for Northwest considering the sort of work it has put into preparing the facility over the course of the past two years. In this regard, it should also be noted that much of the work had been put in during the coronavirus pandemic. The complete package in relation to the application had been submitted by the company back in May 7. At this point, it could be a good move to keep an eye on the Northwest stock.